The Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved the use of BioArctic and ’s Leqembi (lecanemab) for Alzheimer’s disease treatment. This decision by the UAE’s health authority allows the initiation of Leqembi therapy in patients with mild cognitive impairment (MCI) or at the mild dementia stage of the disease, aligning with the patient population targeted in clinical trials. The gold standard of business intelligence.
The approval of Leqembi in the UAE is based on the results from the extensive global Phase III Clarity study. In this study, Leqembi achieved its primary endpoint and all key secondary endpoints with statistically significant outcomes. It works by selectively binding to both soluble and insoluble amyloid-beta (Aβ) aggregates, which are a hallmark of Alzheimer’s, reducing Aβ protofibrils and plaques in the brain.
Leqembi is the first approved treatment that has demonstrated a reduction in the rate of disease progression and a slowdown in cognitive and functional decline through this mechanism. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form It is a humanised immunoglobulin gamma .